中国人群乙型肝炎表面抗原阳性供体肝移植后乙型肝炎病毒

StephenW

J Viral Hepat. 2018 Jul 15. doi: 10.1111/jvh.12972. [Epub ahead of print]
Long-term Outcome and Recurrence of Hepatitis B Virus following Liver Transplantation from Hepatitis B Surface Antigen-positive Donors in a Chinese Population.
Wei L1,2,3,4, Chen D1,2,3,4, Zhang B1,2,3,4, Zhao Y1,2,3,4, Liu B1,2,3,4, Shi H1,2,3,4, Zeng F1,2,3,4, Ming C1,2,3,4, Jiang J1,2,3,4, Du D1,2,3,4, Chen Z1,2,3,4.
Author information

1
    Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HuBei, The People's Republic of China.
2
    Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, HuBei, The People's Republic of China.
3
    NHC Key Laboratory of Organ Transplantation, Wuhan, HuBei, The People's Republic of China.
4
    Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, HuBei, The People's Republic of China.

Abstract

Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen-positive (HBsAg-positive) donors is one possible strategy to increase the donor pool but the long term outcome in a Chinese population is unknown. To evaluate the safety of using of HBsAg-positive donor for liver transplantation, we set up a multicentric retrospective study from January 1, 2007 to December 31, 2012. A total of 8632 patients underwent liver transplantation during the period and 282 (2.97%) received a liver from a HBsAg-positive donor. 259 cases in both the case and control groups were matched. The incidence of postoperative liver dysfunction, early stage and long term complications and the 1-, 3- and 5-year patient survival (78.92% vs 85.65%, 60.41% vs 69.14%, 58.08% vs 69.14%, respectively) showed no difference between the two groups (P value >0.05). However, the 1-, 3- and 5-year HBV recurrence for patients received the HBsAg-positive donor was higher compared with controls (5.85% vs 1.97%, 11.63% vs 4.46%, 17.94% vs 4.46%, respectively, P value =0.016). Our results showed the use of HBsAg-positive donors is feasible and postoperative antiviral therapy should be managed. This article is protected by copyright. All rights reserved.
KEYWORDS:

anti-HBV therapy; hepatitis B surface antigen-positive donor; liver transplantation

PMID:
    30009520
DOI:
    10.1111/jvh.12972

StephenW

J病毒肝病。 2018年7月15日.doi：10.1111 / jvh.12972。 [提前打印]
中国人群乙型肝炎表面抗原阳性供体肝移植后乙型肝炎病毒的长期结局和复发。
Wei L1,2,3,4，Chen D1,2,3,4，Zhang B1,2,3,4，Zhao Y1,2,3,4，Liu B1,2,3,4，Shi H1,2， 3,4，曾F1,2,3,4，明C1,2,3,4，江J1,2,3,4，杜D1,2,3,4，陈Z1,2,3,4。
作者信息

1
    华中科技大学同济医学院附属同济医院器官移植研究所，武汉，中华人民共和国。
2
    中华人民共和国武汉市武汉教育部器官移植重点实验室。
3
    NHC武汉器官移植重点实验室，中华人民共和国湖北省。
4
    中国医学科学院器官移植重点实验室，武汉，中华人民共和国湖北。

抽象

由于中国供体库严重短缺，大量患者正在等待合适的肝脏，甚至更糟糕的是失去了移植的机会。合理使用乙型肝炎表面抗原阳性（HBsAg阳性）供体是增加供体库的一种可能策略，但中国人群的长期结果尚不清楚。为了评估HBsAg阳性供体用于肝移植的安全性，我们在2007年1月1日至2012年12月31日期间开展了一项多中心回顾性研究。期间共有8632例患者接受了肝移植，282例（2.97％）从HBsAg阳性供体接受肝脏。病例组和对照组中的259例相匹配。术后肝功能不全，早期和长期并发症以及1年，3年和5年患者生存率（78.92％vs 85.65％，60.41％vs 69.14％，58.08％vs 69.14％）的发生率无差异两组之间（P值> 0.05）。然而，接受HBsAg阳性供体的患者1年，3年和5年HBV复发率高于对照组（5.85％vs 1.97％，11.63％vs 4.46％，17.94％vs 4.46％，P值= 0.016）。我们的研究结果表明，使用HBsAg阳性供体是可行的，应该对术后抗病毒治疗进行管理。本文受版权保护。版权所有。
关键词：

抗HBV治疗;乙型肝炎表面抗原阳性供体;肝移植

结论：
    30009520
DOI：
    10.1111 / jvh.12972